122110-53-6Relevant articles and documents
Novel Anticancer Prodrugs of Butyric Acid. 2
Nudelman, Abraham,Ruse, Margaretta,Aviram, Adina,Rabizadeh, Ester,Shaklai, Matityahu,et al.
, p. 687 - 694 (1992)
The antitumor activity of novel prodrugs butyric acid was examined.The in vitro effect of the compounds on induction of cytodifferentiation and on inhibition of proliferation and clonogenicity showed that (pivaloyloxy)methyl butyrate (1a) (labeled AN-9) was the most active agent.SAR's suggested that its activity stemmed from hydrolytically released butyric acid.In vivo, 1a displayed antitumor activity in B16FO melanoma primary cancer model, manifested by a significant increase in the life span of the treated animals.Murine lung tumor burden, induced by injection of the highly metastatic melanoma cells (B16F10.9), was decreased by 1a.It also displayed a significant therapeutic activity against spontaneous metastases which were induced by 3LL Lewis lung carcinoma cells.Moreover, 1a has the advantage of low toxicity, with an acute LD50 = 1.36 +/- 0.1 g/kg (n = 5).These results suggest that 1a is a potential antineoplastic agent.
Methods of using butyric acid derivatives to protect against hair loss
-
, (2008/06/13)
The present invention relates to methods of protecting against injury to hair follicles in a mammal by administering an effective amount of butyric acid or a biologically active butyric acid derivative. In particular, this invention relates to the use of cell differentiation-inducing butyric acid derivatives to protect against hair loss in cancer patients undergoing chemotherapy and/or radiation therapy.
Methods of using carboxylic acid esters to increase fetal-hemoglobin levels
-
, (2008/06/13)
This invention relates to novel methods of increasing the level of fetal hemoglobin (HbF) in a subject and methods of treating, preventing or ameliorating β-globin or other HbF-related disorders by increasing the level of HbF in a subject in need of such treatment comprising administering one or more compounds of the Formulae (I), (II), or (III): (I) XCH2 --CHX--CHX--C(=O)--O--Z (II) CH3 --CO--CH2 --C(=O)--O--Z (III) CH3 --CH2 --CO--C(=O)--O--Z wherein: X is H, or one of X only may be OH; Z is --CHR--O--C(=O)R', --CHR--O--C(=O)--O--R', or STR1 R is H, alkyl, aryl, arylalkyl; and R' is alkyl, aminoalkyl, aralkyl, aryl, alkoxy, aralkoxy and aryloxy, in which aryl by itself, and aryl in aralkyl, aralkoxy and aryloxy are each selected from the group consisting of phenyl, naphthyl, furyl, or thienyl, each of which is unsubstituted or substituted by at least one substituent selected from the group consisting of alkyl, alkoxy, or halogen; and pharmaceutically acceptable salts and prodrugs thereof.
Biologically active carboxylic acid esters
-
, (2008/06/13)
Biologically active carboxylic acid esters which promote antitumor or immune response are selected from the group consisting of compounds having formulas (I), (II) and (III):XCH 2 --CHX--CHX--C( O)--O--Z (I)CH 3 --CO--CH 2 --C( O)--O--Z (II)CH 3 --CH 2 --CO--C( O)--O--Z (III)wherein X is H, or one X only may be OH; Z is --CHR--O--(O )C--R'', R represents a member selected from the group consisting of hydrogen and alkyl, and R'' represents a member of the group consisting of alkyl, aminoalkyl, aralkyl, aryl, alkoxy, aralkoxy and aryloxy, in which aryl by itself, and aryl in aralkyl, aralkoxy and aryloxy, are each selected from the group consisting of sub-groups (a) and (b), wherein (a) is unsubstituted phenyl, napthyl, furyl or thienyl, and (b) is phenyl, napthyl, furyl or thienyl, each of which is substituted by at least one substituent selected from the group consisting of alkyl, alkoxy or halogen, provided that in (I) when X is H and R'' is propyl, then R is alkyl which contains at least three carbon atoms.
